Lymphotoxin Signaling Is Initiated by the Viral Polymerase in HCV-linked Tumorigenesis
暂无分享,去创建一个
M. Karin | J. Piette | P. Lassus | U. Hibner | D. Durantel | A. Rosenberg | Y. Simonin | L. Akkari | Guann-Yi Yu | S. Vegna | Damien Grégoire | E. Antoine | Nicolas Floc'h | Nicolas Floc’h
[1] Céline Hernandez,et al. Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors. , 2012, Journal of hepatology.
[2] M. Karin,et al. Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. , 2012, Molecular cell.
[3] V. Nizet,et al. Anthrax toxin induces macrophage death by p38 MAPK inhibition but leads to inflammasome activation via ATP leakage. , 2011, Immunity.
[4] K. Bhardwaj,et al. A Cell-Based Assay for RNA Synthesis by the HCV Polymerase Reveals New Insights on Mechanism of Polymerase Inhibitors and Modulation by NS5A , 2011, PloS one.
[5] S. Lemon,et al. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer , 2011, Oncogene.
[6] B. Aggarwal,et al. NF-κB addiction and its role in cancer: ‘one size does not fit all’ , 2011, Oncogene.
[7] R. Silverman,et al. RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. , 2010, RNA.
[8] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[9] M. Karin,et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. , 2010, Cancer cell.
[10] Jian Shi,et al. High expression levels of IKKα and IKKβ are necessary for the malignant properties of liver cancer , 2010, International journal of cancer.
[11] P. Allavena,et al. The chemokine system in cancer biology and therapy. , 2010, Cytokine & growth factor reviews.
[12] P. Bioulac-Sage,et al. Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway , 2009, Hepatology.
[13] M. Kurrer,et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. , 2009, Cancer cell.
[14] S. Lemon,et al. Impaired Replication of Hepatitis C Virus Containing Mutations in a Conserved NS5B Retinoblastoma Protein-Binding Motif , 2009, Journal of Virology.
[15] Y. Ben-Neriah,et al. Contradictory functions of NF-kappaB in liver physiology and cancer. , 2008, Cancer letters.
[16] C. Ware. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways , 2008, Immunological reviews.
[17] J. Browning. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease , 2008, Immunological reviews.
[18] P. Lassus,et al. Transforming growth factor beta controls the directional migration of hepatocyte cohorts by modulating their adhesion to fibronectin. , 2007, Molecular biology of the cell.
[19] F. Ciardiello,et al. Chronic inflammation and oxidative stress in human carcinogenesis , 2007, International journal of cancer.
[20] A. Talal,et al. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection , 2007, Journal of viral hepatitis.
[21] A. Molla,et al. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology , 2007, Hepatology.
[22] Michael Karin,et al. Regulation and Function of IKK and IKK-Related Kinases , 2006, Science's STKE.
[23] M. Griguoli,et al. Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin β receptor-Ig fusion protein , 2006, Journal of Neuroimmunology.
[24] J. Symons,et al. In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance. , 2006, Virology.
[25] M. Levrero. Viral hepatitis and liver cancer: the case of hepatitis C , 2006, Oncogene.
[26] A. Shavinskaya,et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[27] Victor V. Keasler,et al. Increased liver pathology in hepatitis C virus transgenic mice expressing the hepatitis B virus X protein. , 2006, Virology.
[28] L. Coussens,et al. Inflammation, proteases and cancer. , 2006, European journal of cancer.
[29] M. Otto,et al. Inhibition of Hepatitis C Replicon RNA Synthesis by β-D-2′-deoxy-2′-fluoro-2′-C-Methylcytidine: A Specific Inhibitor of Hepatitis C Virus Replication , 2006, Antiviral chemistry & chemotherapy.
[30] Junji Kato,et al. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor α expression via activation of nuclear factor-κB , 2006, Gut.
[31] F. Chisari,et al. Immunobiology and pathogenesis of viral hepatitis. , 2006, Annual review of pathology.
[32] K Takada,et al. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. , 2006, Gut.
[33] Yuqiong Liang,et al. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[34] W. Stec,et al. Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. , 2005, Journal of medicinal chemistry.
[35] Michael Karin,et al. IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.
[36] D. Burton,et al. Robust hepatitis C virus infection in vitro. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] Michael Karin,et al. NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.
[38] C. Ware. Network communications: lymphotoxins, LIGHT, and TNF. , 2005, Annual review of immunology.
[39] D. Golenbock,et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. , 2004, Gastroenterology.
[40] Y. Ben-Neriah,et al. NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.
[41] M. Karin,et al. The two NF-κB activation pathways and their role in innate and adaptive immunity , 2004 .
[42] F. Fuller-Pace,et al. Cellular RNA Helicase p68 Relocalization and Interaction with the Hepatitis C Virus (HCV) NS5B Protein and the Potential Role of p68 in HCV RNA Replication , 2004, Journal of Virology.
[43] M. Karin,et al. The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer , 2004 .
[44] S. Lemon,et al. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. , 2004, Gastroenterology.
[45] Luca Mascitelli,et al. Viral hepatitis C , 2004, The Lancet.
[46] Rinat Abramovitch,et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.
[47] M. Karin,et al. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. , 2004, Trends in immunology.
[48] M. Karin,et al. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. , 2004, Cancer letters.
[49] M. Karin,et al. IKKβ Is Required for Prevention of Apoptosis Mediated by Cell-Bound but Not by Circulating TNFα , 2003 .
[50] A. Siddiqui,et al. Hepatitis C Virus NS5A and Subgenomic Replicon Activate NF-κB via Tyrosine Phosphorylation of IκBα and Its Degradation by Calpain Protease* , 2003, Journal of Biological Chemistry.
[51] Rakesh K. Kumar,et al. Expression of the chemokine IP‐10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation , 2003, Journal of leukocyte biology.
[52] J. Olynyk,et al. Upregulation of lymphotoxin β expression in liver progenitor (oval) cells in chronic hepatitis C , 2003 .
[53] G. Ramadori,et al. Expression of the chemokine IP‐10 correlates with the accumulation of hepatic IFN‐γ and IL‐18 mRNA in chronic hepatitis C but not in hepatitis B , 2003, Journal of medical virology.
[54] S. Nedospasov,et al. The role of lymphotoxin in development and maintenance of secondary lymphoid tissues. , 2003, Cytokine & growth factor reviews.
[55] Lawrence C Kuo,et al. Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs* , 2003, The Journal of Biological Chemistry.
[56] M. Karin,et al. IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. , 2003, Immunity.
[57] J. Olynyk,et al. Upregulation of lymphotoxin beta expression in liver progenitor (oval) cells in chronic hepatitis C. , 2003, Gut.
[58] A. Siddiqui,et al. Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. , 2003, The Journal of biological chemistry.
[59] A. Siddiqui,et al. Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-kappaB and STAT-3. , 2002, Biochemical pharmacology.
[60] Christian Trepo,et al. Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[61] J. Hoofnagle. Course and outcome of hepatitis C , 2002, Hepatology.
[62] K. Kyono,et al. Human eukaryotic initiation factor 4AII associates with hepatitis C virus NS5B protein in vitro. , 2002, Biochemical and biophysical research communications.
[63] S. Lemon,et al. Selectable Subgenomic and Genome-Length Dicistronic RNAs Derived from an Infectious Molecular Clone of the HCV-N Strain of Hepatitis C Virus Replicate Efficiently in Cultured Huh7 Cells , 2002, Journal of Virology.
[64] C. Abbott,et al. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. , 2002, The American journal of pathology.
[65] M. Honda,et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. , 2002, Gastroenterology.
[66] Y. Shirota,et al. Mutational analysis of the structure and functions of hepatitis C virus RNA–dependent RNA polymerase , 2001, Hepatology.
[67] G. Fourel,et al. Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of β-catenin and synergistic effect of p53 null alleles , 2000, Oncogene.
[68] T. Libermann,et al. Adenovirus Vector-Induced Expression of the C-X-C Chemokine IP-10 Is Mediated through Capsid-Dependent Activation of NF-κB , 2000, Journal of Virology.
[69] Yan-Hwa Wu Lee,et al. Hepatitis C Virus Core Protein Enhances NF-κB Signal Pathway Triggering by Lymphotoxin-β Receptor Ligand and Tumor Necrosis Factor Alpha , 1999, Journal of Virology.
[70] H. Hotta,et al. Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus. , 1998, Biochemical and biophysical research communications.
[71] Yan-Hwa Wu Lee,et al. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor , 1997, Journal of virology.
[72] C. Ambrose,et al. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. , 1997, Journal of immunology.
[73] F. Mackay,et al. Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs , 1996, The Journal of experimental medicine.